NR2F6 as a Prognostic Biomarker in HNSCC
Standard
NR2F6 as a Prognostic Biomarker in HNSCC. / Klapper, Luise; Ribbat-Idel, Julika; Kuppler, Patrick; Paulsen, Finn-Ole; Bruchhage, Karl-Ludwig; Rades, Dirk; Offermann, Anne; Kirfel, Jutta; Wollenberg, Barbara; Idel, Christian; Perner, Sven.
in: INT J MOL SCI, Jahrgang 21, Nr. 15, 5527, 01.08.2020.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - NR2F6 as a Prognostic Biomarker in HNSCC
AU - Klapper, Luise
AU - Ribbat-Idel, Julika
AU - Kuppler, Patrick
AU - Paulsen, Finn-Ole
AU - Bruchhage, Karl-Ludwig
AU - Rades, Dirk
AU - Offermann, Anne
AU - Kirfel, Jutta
AU - Wollenberg, Barbara
AU - Idel, Christian
AU - Perner, Sven
PY - 2020/8/1
Y1 - 2020/8/1
N2 - Head and neck squamous cell carcinoma (HNSCC)is the 6th most common cancer in humans worldwide and is associated with a poor prognosis for patients. NR2F6 has been identified as an immune checkpoint molecule in tumor-infiltrating T lymphocytes and is associated with a poor prognostic outcome in various cancers. The prognostic value of NR2F6 in HNSCC has not been described yet. We used a large, representative and clinically well-characterized cohort of 383 HNSCC patients, of which 22.4% developed a local recurrence. The NR2F6 expression was analyzed by using immunohistochemistry and was afterward correlated with clinical characteristics and clinicopathological features of HNSCC patients. Primary tumors from patients who develop a local recurrence have a higher NR2F6 expression than primary tumors which do not develop a local recurrence. Furthermore, a high NR2F6 expression is associated with poorer recurrence-free survival, although there is no correlation with overall survival. NR2F6 expression is independent of the T stage and UICC stage. NR2F6 might be a new prognostic biomarker for the early detection of local recurrences in HNSCC patients. Therefore, it may help to improve the recognition of patients who would benefit from more frequent follow-up examinations.
AB - Head and neck squamous cell carcinoma (HNSCC)is the 6th most common cancer in humans worldwide and is associated with a poor prognosis for patients. NR2F6 has been identified as an immune checkpoint molecule in tumor-infiltrating T lymphocytes and is associated with a poor prognostic outcome in various cancers. The prognostic value of NR2F6 in HNSCC has not been described yet. We used a large, representative and clinically well-characterized cohort of 383 HNSCC patients, of which 22.4% developed a local recurrence. The NR2F6 expression was analyzed by using immunohistochemistry and was afterward correlated with clinical characteristics and clinicopathological features of HNSCC patients. Primary tumors from patients who develop a local recurrence have a higher NR2F6 expression than primary tumors which do not develop a local recurrence. Furthermore, a high NR2F6 expression is associated with poorer recurrence-free survival, although there is no correlation with overall survival. NR2F6 expression is independent of the T stage and UICC stage. NR2F6 might be a new prognostic biomarker for the early detection of local recurrences in HNSCC patients. Therefore, it may help to improve the recognition of patients who would benefit from more frequent follow-up examinations.
KW - Biomarkers, Tumor/biosynthesis
KW - Carcinoma, Squamous Cell/diagnosis
KW - Female
KW - Head and Neck Neoplasms/diagnosis
KW - Humans
KW - Immunohistochemistry
KW - Kaplan-Meier Estimate
KW - Male
KW - Middle Aged
KW - Neoplasm Recurrence, Local
KW - Neoplasm Staging
KW - Prognosis
KW - Repressor Proteins/biosynthesis
KW - Retrospective Studies
U2 - 10.3390/ijms21155527
DO - 10.3390/ijms21155527
M3 - SCORING: Journal article
C2 - 32752295
VL - 21
JO - INT J MOL SCI
JF - INT J MOL SCI
SN - 1661-6596
IS - 15
M1 - 5527
ER -
